Therapy of bovine ocular squamous-cell carcinoma with local doses of interleukin-2: 67% complete regressions after 20 months of follow-up

F. W. Willem Den Otter*, Graham Hill, Wim R. Klein, Jan Willem Koten, Peter A. Steerenberg, Pieter H M De Mulder, Christopher Rhode, Rachel Stewart, Joop A J Faber, E. Joost Ruitenberg, Victor P M G Rutten

*Corresponding author for this work

    Research output: Contribution to journalArticleAcademicpeer-review

    Abstract

    We have tested the therapeutic potency of peritumorally injected low doses of interleukin-2(IL-2). Seventy tumours of the bovine ocular squamous-cell carcinoma (BOSCC), 1-3 cm in diameter, were treated with 5000, 20 000 or 200 000 U IL-2 from Eurocetus (Chiron) to find the optimal dose for treatment. Injections were given peritumorally on Monday to Friday on 2 consecutive weeks. The size of the tumours was measured before treatment and 1, 3, 4, 9 and 20 months after treatment. After 9 months complete regression was observed in 89% of the tumours treated with 5000 U IL-2, 80% treated with 20 000 U and 67% treated with 200 000 U. After 20 months, there was complete regression of 35%, 31% and 67% of the tumours respectively. The 9-and 20-month results of the 200 000-U treatment are significantly better than those of the 5000-U and 20 000-U treatments taken together. This protocol may be useful to treat advanced inoperable tumours (e.g. of the nasopharynx or skin) of human patients.

    Original languageEnglish
    Pages (from-to)10-14
    Number of pages5
    JournalCancer Immunology Immunotherapy
    Volume41
    Issue number1
    DOIs
    Publication statusPublished - 1 Jan 1995

    Keywords

    • Cancer
    • IL-2 therapy
    • Immunotherapy Bovine ocular squamous-cell carcinoma

    Fingerprint

    Dive into the research topics of 'Therapy of bovine ocular squamous-cell carcinoma with local doses of interleukin-2: 67% complete regressions after 20 months of follow-up'. Together they form a unique fingerprint.

    Cite this